🥊 The compounding battle continues

Change hasn't come quickly -- the battle around compounding is still raging.

Last year, Tirzepatide coming off the shortage list might have been the most disruptive event for people who depend on being able to cheaply purchase GLP1s.

The situation is still tenuous for comopunders — while suing the FDA provided a brief reprieve (and the FDA subsequently essentially promised not to take legal actions against compounders), the situation can’t last forever.

We take a look at what’s changed since then — are we any closer to a resolution, or still in the gray zone?